It was a smart decision to rapidly develop a rapid antigen test for the detection of Cobid-19 back in 2020. The test having since become available in the US, sales grew significantly in line with infection rates. Test sales will decline in H2 as the planet seems to be moving from a pandemic to an endemic situation although the underlying businesses are expected to recover strongly over the forecast period.
Consensus was beaten by +4.1% on the top-line and adjusted EBIT by +6.9%.
04 May 2022
Strong growth despite headwinds
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong growth despite headwinds
It was a smart decision to rapidly develop a rapid antigen test for the detection of Cobid-19 back in 2020. The test having since become available in the US, sales grew significantly in line with infection rates. Test sales will decline in H2 as the planet seems to be moving from a pandemic to an endemic situation although the underlying businesses are expected to recover strongly over the forecast period.
Consensus was beaten by +4.1% on the top-line and adjusted EBIT by +6.9%.